Who are Ipratropium / Levosalbutamol Fixed Dose Combination's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ipratropium-levosalbutamol-fixed-dose-combination.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Ipratropium / Levosalbutamol Fixed Dose Combination — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ipratropium / Levosalbutamol Fixed Dose Combination (Ipratropium / Levosalbutamol Fixed Dose Combination) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticholinergic / Short-acting beta-2 agonist combination. Area: Respiratory / Pulmonology.

phase 3 Anticholinergic / Short-acting beta-2 agonist combination Muscarinic acetylcholine receptors (ipratropium); Beta-2 adrenergic receptor (levosalbutamol) Respiratory / Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

Ipratropium / Levosalbutamol Fixed Dose Combination (Ipratropium / Levosalbutamol Fixed Dose Combination) — Neutec Ar-Ge San ve Tic A.Ş. This combination drug relaxes airway muscles through dual action: ipratropium blocks acetylcholine receptors to reduce bronchoconstriction, while levosalbutamol stimulates beta-2 adrenergic receptors to promote bronchodilation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ipratropium / Levosalbutamol Fixed Dose Combination TARGET	Ipratropium / Levosalbutamol Fixed Dose Combination	Neutec Ar-Ge San ve Tic A.Ş	phase 3	Anticholinergic / Short-acting beta-2 agonist combination	Muscarinic acetylcholine receptors (ipratropium); Beta-2 adrenergic receptor (levosalbutamol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticholinergic / Short-acting beta-2 agonist combination class)

Neutec Ar-Ge San ve Tic A.Ş · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ipratropium / Levosalbutamol Fixed Dose Combination — Competitive Intelligence Brief. https://druglandscape.com/ci/ipratropium-levosalbutamol-fixed-dose-combination. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing